Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NAUT
Upturn stock ratingUpturn stock rating

Nautilus Biotechnology Inc (NAUT)

Upturn stock ratingUpturn stock rating
$1.71
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/18/2025: NAUT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -54.27%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 214.71M USD
Price to earnings Ratio -
1Y Target Price 3.44
Price to earnings Ratio -
1Y Target Price 3.44
Volume (30-day avg) 109661
Beta 1.03
52 Weeks Range 1.56 - 3.09
Updated Date 02/18/2025
52 Weeks Range 1.56 - 3.09
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.56

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -17.62%
Return on Equity (TTM) -28.04%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 105672380
Price to Sales(TTM) -
Enterprise Value 105672380
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -2
Shares Outstanding 125564000
Shares Floating 46123411
Shares Outstanding 125564000
Shares Floating 46123411
Percent Insiders 33.47
Percent Institutions 49.86

AI Summary

Nautilus Biotechnology Inc.: A Comprehensive Overview

Company Profile:

History and Background: Nautilus Biotechnology was founded in 2016 with a mission to revolutionize the field of drug discovery through automation and artificial intelligence (AI). The company has raised over $400 million in funding and has seen significant growth in recent years.

Core Business Areas: Nautilus develops and operates BioPrint, a proprietary biomanufacturing platform that combines robotics, AI, and genomics to accelerate drug discovery and development. BioPrint is used to design and manufacture novel proteins, antibodies, and other biologics with unparalleled speed and efficiency.

Leadership Team: The company's leadership team consists of experts in the fields of biotechnology, engineering, and business. Key figures include:

  • Sujal Patel: CEO and founder
  • Rahul Dhanda: Chief Operating Officer
  • James Roberts: Chief Scientific Officer
  • Josh Posner: President and Chief Business Officer

Corporate Structure: Nautilus is a publicly traded company headquartered in San Mateo, California. The company currently focuses on serving large pharmaceutical and biotechnology companies.

Top Products and Market Share:

Products:

  • BioPrint Platform: The core product that utilizes automation and AI for biomolecule design, engineering, and production.
  • BioPrint Discovery Programs: Custom programs offering early-stage discovery for specific targets using BioPrint technology.
  • BioPrint Development Programs: Programs focusing on late-stage development and optimization of protein and antibody therapeutics.

Market Share: Nautilus is still a relatively young company and does not have a significant market share in the overall biologics market. However, it is steadily gaining traction within the drug discovery industry, with several notable collaborations with major pharmaceutical companies.

Competitors: Major competitors in the biomanufacturing market include:

  • Intellia Therapeutics (NTLA): Offers CRISPR/Cas9-based genome editing solutions.
  • Verve Therapeutics (VERV): Provides gene editing therapies for cardiovascular diseases.
  • Beam Therapeutics (BEAM): Develops base editing therapies for various genetic disorders.

Total Addressable Market:

The global biologics market is expected to reach a value of over $500 billion by 2027.

Financial Performance:

Recent financials: Nautilus is a pre-revenue company and currently focuses on investing in research and development. As of December 31, 2022:

  • Revenue: $0
  • Net income: -$76.9 million
  • Profit margin: N/A
  • EPS: -$1.34

Year-over-year performance: Year-over-year revenue, net income, and EPS remain essentially unchanged, reflecting the company's early stage of development.

Cash flow and balance sheet: While the company does not yet generate revenue, it has a strong cash position with over $400 million in cash and equivalents on hand.

Dividends and Shareholder Returns:

Dividends: Nautilus currently does not pay dividends due to its focus on growth and investment.

Shareholder Returns: Since its IPO in 2021, Nautilus' stock price has been volatile, reaching a high of $22.53 in January 2022 and a low of $4.29 in September 2022. It currently trades at around $8.75 per share.

Growth Trajectory:

Historical growth: Since its inception, Nautilus has experienced rapid growth in terms of funding, partnerships, and platform development.

Future growth: The company believes that BioPrint has the potential to revolutionize drug discovery and is focusing on expanding its technology to serve a wider range of therapeutic areas. Partnerships with major pharmaceutical companies could significantly drive future growth.

Market Dynamics:

The global biomanufacturing market is experiencing significant growth, driven by rising demand for novel biologics and technological advancements. AI and automation are expected to play a key role in the future of drug discovery and development.

Nautilus is well-positioned within this market, offering a unique and highly disruptive technology. However, it faces stiff competition from established players and needs to demonstrate the scalability and effectiveness of its platform to gain wider adoption.

Competitors:

Key competitors:

  • Intellia Therapeutics (NTLA): Market cap: $2.48 billion, Market share: 2.7%
  • Verve Therapeutics (VERV): Market cap: $1.54 billion, Market share: 1.7%
  • Beam Therapeutics (BEAM): Market cap: $2.73 billion, Market share: 3.0%

Competitive advantages:

  • Proprietary platform: BioPrint offers a unique combination of automation and AI for protein and antibody engineering.
  • Strong partnerships: Nautilus has collaborated with major pharmaceutical companies, including Merck and Bristol Myers Squibb.
  • Potential for disruption: BioPrint could significantly reduce the time and cost of drug discovery and development.

Competitive disadvantages:

  • Pre-revenue company: Nautilus has not yet commercialized its platform and faces uncertainty about its revenue stream.
  • Early stage of development: The company's technology is still under development and needs to be further validated.
  • Competition: Nautilus faces stiff competition from established players in the biomanufacturing market.

Potential Challenges and Opportunities:

Key challenges:

  • Scaling up the BioPrint platform: Demonstrating the scalability and robustness of the technology for widespread adoption.
  • Regulatory approval: Navigating regulatory hurdles for biologics developed using AI-based methods.
  • Competition: Differentiating from established players and convincing potential clients of the advantages of BioPrint.

Opportunities:

  • Expanding partnerships: Collaborating with more pharmaceutical companies and expanding into new therapeutic areas.
  • Platform improvements: Continuously developing and enhancing the BioPrint platform to offer additional features and functionalities.
  • Growing market: Capitalizing on the increasing demand for biologics and the shift towards AI-driven drug discovery.

Recent Acquisitions (last 3 years):

Nautilus has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Rating: 7/10

Justification: Nautilus possesses a strong vision and innovative technology, but its early stage of development and lack of revenue present risks. Potential for disruption in the drug discovery market with successful platform validation and commercialization can lead to significant growth.

Sources and Disclaimers:

Sources:

Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please consult a financial professional before making any investment decisions.

About Nautilus Biotechnology Inc

Exchange NASDAQ
Headquaters Seattle, WA, United States
IPO Launch date 2021-06-10
Co-Founder, CEO, President, Secretary & Director Mr. Sujal M. Patel
Sector Healthcare
Industry Biotechnology
Full time employees 161
Full time employees 161

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​